| PATENT NUMBER | This data is not available for free |
| PATENT GRANT DATE | April 6, 1999 |
| PATENT TITLE |
Environmentally safe triancinolone acetonide aerosol formulations for oral inhalation |
| PATENT ABSTRACT | Aerosol formulations for oral inhalation containing triamcinolone acetonide and HFC 134a and/or HFC 227 as a propellant which are free of chlorofluorocarbons and surfactants are disclosed |
| PATENT INVENTORS | This data is not available for free |
| PATENT ASSIGNEE | This data is not available for free |
| PATENT FILE DATE | April 21, 1997 |
| PATENT REFERENCES CITED |
Saunders, "Handbook of Aerosol Technology" 2nd ed. pp. 30-35, 166-167, and 232-233, Von Nostrand Reinhold Co. (1979). DuPont Update "Fluorocarbon/Ozone", published by DuPont, Willington, DE (Mar. 1987). Dictionnaire Vidal, 55th ed. pp. 547-548, O.V.P. Paris (1979). M. Jones, New Scientist, pp. 56-59, May 26, 1988. Manufacturing Chemist, p. 3, Jun. 1988. Organic Chemicals Department, E.I. Du Pont de Nemocers & Co., Research Disclosure, p. 70, Oct. 1977. H.O. Spauschus, Rev. Int. Froid., vol. 11, pp. 389-392 (1988). D.R. Strobach, Aerosol Age, pp. 32-43 (1988). |
| PATENT CLAIMS |
What is claimed is: 1. An aerosol formulation consisting of: a) a therapeutically effective amount of micronized triamcinolone acetonide; b) a propellant selected from the group consisting of HFC 134a, HFC 227 and a mixture thereof wherein the amount of chloroflurocarbon in the propellant is less than 0.01% by weight of the formulation; c) from about 1% to about 3% ethanol; and d) optionally flavoring agents or taste-mask or excipients, wherein the particle size of the micronized drug powder is less than 100 microns in diameter. 2. The formulation of claim 1, wherein said triamcinolone acetonide is present in an amount from about 0.01% to about 2% by weight of the formulation. 3. The formulation of claim 2, wherein said triamcinolone acetonide is present in an amount from about 0.10% to about 1.5% by weight of the formulation. 4. The formulation of claim 3, wherein said triamcinolone acetonide is present in an amount from about 0.30% to about 0.40% by weight of the formulation. 5. The formulation of claim 1, wherein said propellant is HFC 134a. 6. The formulation of claim 1, wherein said propellant is HFC 227. 7. The formulation of claim 1, wherein said propellant is a mixture of HFC 134a and HFC 227. 8. The formulation of claim 1, wherein the particle size of said micronized triamcinolone acetonide is less than about 10 microns. 9. The formulation of claim 5, wherein the particle size of said micronized triamcinolone acetonide is from about 0.5 to about 5.0 microns. -------------------------------------------------------------------------------- |
| PATENT DESCRIPTION |
FIELD OF THE INVENTION This invention relates to triamcinolone acetonide aerosol formulations for oral inhalation and, more particularly, to such formulations which are free of chlorofluorocarbons and surfactants. BACKGROUND OF THE INVENTION Drugs for treating respiratory disorders are frequently administered in oral aerosol formulations. One widely used method for dispensing such an aerosol drug formulation involves making a formulation of the drug in a liquified gas known as a propellant. The drug may be dissolved or suspended in the propellant, or in a combination slurry-solution. The formulation is dispensed by actuation of a dose metering valve affixed to the container the valve being designed to consistently release a fixed, predetermined amount of the drug formulation upon each activation. As the formulation is forced from the container through the dose metering valve by the high vapor pressure of the propellant, the propellant rapidly vaporizes, leaving a fast-moving cloud of very fine particles or droplets of the drug formulation. This cloud is then directed into the mouth of the patient. Concurrently with the activation of the aerosol dose metering valve, the patient inhales the drug formulation particles into the lungs. Systems for dispensing drugs in this way are known as metered dose inhalers (MDIs). Chlorofluorocarbons (CFCs) have been used extensively as propellants in drug formulations that are delivered to patients via an MDI. However, recent scientific evidence suggests that CFCs damage the Earth's ozone layer. It is believed that ozone blocks harmful ultraviolet rays and that depletion of the ozone layer will result in the incidence of skin cancer. As a result, steps have been taken to reduce CFC production and usage, and recent recommendations have been made that CFC production be virtually discontinued by the end of this century. Until recently, however, few propellant systems have been discovered which are suitable alternatives to the use of CFCs in MDIs. The nonchlorinated propellants 1,1,1,2-tetrafluoroethane, also known as hydrofluorocarbon (HFC) 134a, and 1,1,1,2,3,3,3-heptafluoropropane, also known as HFC 227, are among the leading candidates for replacement of the ozone-damaging CFC propellants. However, the substitution of a non-CFC propellant for the CFC propellants in MDI formulations is not straightforward. There are drug solubility, drug stability and deliverability problems as well as particle size issues which must be addressed when substituting propellants in an MDI formulation. MDIs contain drugs which are dissolved or suspended as micronized particles, propellants in the form of liquified gases, and surface active compounds, or "surfactants," of a type and in a concentration suitable for suspension or dissolution of the drug. Surfactants are included in the formulation to improve particle dispersibility, prevent deaggregation and improve valve function by virtue of its lubricating properties. In some solution formulations, a co-solvent may be added to enhance drug dissolution, although this practice may have the disadvantage of decreasing the fraction of the metered dose which may be inhaled and contributing to particle size growth. HFC 134a, or 1,1,1,2-tetrafluoroethane (the names will be used interchangeably herein) is nonflammable, has low toxicity and has vapor pressure suitable for use in aerosols. However, HFC 134a is a very poor solvent which fails to dissolve or adequately disperse commonly used surfactants such as sorbitan trioleate, sorbitan monooleate, lecithins and oleic acid in useful concentrations without the aid of a co-solvent. Similarly, HFC 227, or 1,1,1,2,3,3,3-heptafluro-propane (the names will be used interchangeably herein) is nonflammable, has low toxicity and has a vapor pressure suitable for use in aerosols. However, the polarity and solubility of HFC 227 differ from those of commonly used CFC propellants, and many commonly used surfactants are not soluble or are poorly dispersible in HFC 227. Triamcinolone acetonide is an anti-inflammatory glucocorticosteriod having the chemical name 9-fluoro-1.beta., 16.alpha.,17,21-tetrahydroxy-pregna-1,4-diene-3,20-dione cyclic 16,17-acetal with acetone. Triamcinolone acetonide is useful for the control of the symptoms of bronchial asthma and in the treatment of seasonal and perennial allergic rhinitis symptoms. Presently available triamcinolone acetonide formulations for MDIs utilize CFCs such as dichlorodifluoromethane as the propellant. Thus, there remains a need for an environmentally safe triamcinolone acetonide formulation for MDIs utilizing hydrofluorocarbon propellants such as HFC 134a and HFC 227. Numerous attempts have been made to formulate aerosols for oral inhalation using non-ozone depleting propellants. However, these formulations generally require the addition of surfactants, polar cosolvents or other adjuvants, and some require the additional manufacturing step of precoating the drug particles with a surfactant prior to dispersal in the propellant. For example, U.S. Pat. No. 5,225,183 to Purewal et al. discloses MDI formulations which include HFC 134a, a surface active agent, and an adjuvant compound having a higher polarity than HFC 134a. The inclusion of a higher polarity compound in the formulation is said to be critical to the stability and performance of the MDI formulation. The surface active agent is used to stabilize the formulation and lubricate the valve components. U.S. Pat. No. 5,492,688 to Byron et al. relates to MDI formulations which utilize HFC 134a as the propellant and include a polar surfactant for suspending, solubilizing, wetting and emulsifying the drug constituent and lubricating the valve components of the MDI. U.S. Pat. No. 5,182,097 to Byron et al. relates to aerosol formulations consisting of 1,1,1,2-tetrafluoroethane, a drug and oleic acid as a surfactant to aid in dispersing the drug in the propellant. International Application Publication No. WO91/04011 relates to medicinal aerosol formulations in which the micronized drug particles are pre-coated with a surfactant prior to dispersal in 1,1,1,2-tetrafluoroethane. It has now been surprisingly found that HFC 134a and HFC 227 may be used as propellants for medicinal aerosol formulations containing triamcinolone acetonide without the need for a surfactant and without the need to pre-coat the drug prior to dispersal in the propellant. SUMMARY OF THE INVENTION This invention relates to an aerosol formulation which is substantially free of chlorofluorocarbons and surfactants and which comprises a therapeutically effective amount of micronized triamcinolone acetonide, a propellant selected from the group consisting of HFC 134a, HFC 227 and a mixture thereof and, optionally, ethanol. In a preferred embodiment, triamcinolone acetonide is present in an amount from about 0.01% to about 2% by weight of the formulation. In a more preferred embodiment, triamcinolone acetonide is present in an amount from about 0.10% to about 1.5% by weight of the formulation. In a most preferred embodiment, triamcinolone acetonide is present in an amount from about 0.30% to about 0.40% by weight of the formulation. Additionally, this invention relates to a method for treating a respiratory disorder in a patient by administering to the patient an effective amount of an aerosol formulation which is substantially free of chlorofluorocarbons and surfactant and which comprises a therapeutically effective amount of micronized triamcinolone acetonide, a propellant selected from the group consisting of HFC 134a, HFC 227 and a mixture thereof and, optionally, ethanol. In a preferred embodiment, the respiratory disorder is bronchial asthma. This invention also relates to a metered dose inhaler suitable for delivering an aerosol formulation. The metered dose inhaler comprises a container capable of withstanding the vapor pressure of the propellant used, and an aerosol formulation substantially free of chlorofluorocarbons and surfactants contained in the container. The formulation comprises a therapeutically effective amount of micronized triamcinolone acetonide and a propellant selected from the group consisting of HFC 134a, HFC 227 and a mixture thereof. The container is closed with a metering valve having a gasket. In a preferred embodiment, the gasket is made from white nitrile rubber. In another preferred embodiment, the gasket is made from ethylene-propylene-diene monomers (EPDM) rubber. DETAILED DESCRIPTION OF THE INVENTION The present invention provides an aerosol formulation comprising a therapeutically effective amount of triamcinolone acetonide and a propellant comprising a hydrofluorocarbon selected from the group consisting of 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane, and a mixture thereof. The formulation is substantially free of chlorofluorocarbons and surfactants. Optionally, ethanol may be included in an amount effective to wet and aid in dispersing the triamcinolone acetonide in the formulation. For purposes of the present invention the term "substantially free of chlorofluorocarbons and surfactants" is intended to mean containing no significant amounts of chlorofluorocarbons or surfactants, i.e. less than 0.01% by weight of the formulation. HFC 134a and/or HFC 227 are generally present in the formulations of the present invention in an amount of at least 90% by weight of the formulation, and preferably greater than 95% by weight of the formulation. Most preferably, the propellants are present in an amount from about 98.5% to about 99.75% by weight of the formulation. Triamcinolone acetonide is virtually insoluble in HFC 134a and HFC 227. The concentration of triamcinolone acetonide in the formulations of the present invention depends upon the desired dosage, but is generally between about 0.005% and about 5% of the formulation by weight, and preferably comprises from about 0.01% to about 2% by weight of the formulation. More preferably, triamcinolone acetonide comprises from about 0.10% to about 1.5% by weight of the formulation. Most preferably, triamcinolone acetonide comprises from about 0.30% to about 0.40% of the formulation. In formulations of the present invention where ethanol is present, it comprises less than 5% of the formulation. Preferably ethanol is present in an amount from about 1% to about 3% by weight of the formulation. More preferably, ethanol is present in an amount from about 1% to about 2% by weight of the formulation. The particle size of the powder should be no greater than 100 microns diameter, since larger particles may clog the valve or orifice of the container. Preferably substantially all of the particles should be less than 25 microns in diameter. More preferably substantially all of the particles should be less than about 10 microns in diameter. Most preferably substantially all of the particles should be from about 0.5 to about 5 microns in diameter. There is no lower limit on particle size except that which will be readily absorbed and retained on or in body tissues. When particles of less than about one-half micron in diameter are administered by inhalation, they tend to be exhaled by the patient. Flavoring or taste-masking agents optionally may be added to the compositions of the instant invention. Suitable flavoring agents will be known to the skilled artisan. Preferred flavoring agents include menthol and peppermint oil and combinations thereof. The flavoring agent is preferably present in an amount effective to mask the taste of the drug when an aerosolized dose of the formulation is inhaled orally. In general, amounts of about 0.01% to about 5.0% by weight of the composition are used with amounts of about 0.05% to about 1.0% by weight being preferred. In addition to flavoring agents, other excipients may be added to an aerosol formulation to improve drug delivery, shelf life and patient acceptance. Such optional excipients include, but are not limited to, buffers, antioxidants and chemical stabilizers. Such excipients must be non-reactive with the drug and relatively non-toxic. The vapor pressure of the excipients should be such that the overall formula vapor pressure should be below 80 psig at room temperature. The formulations of the present invention may be filled into conventional aerosol containers equipped with metering valves using conventional filling equipment well known to those skilled in the art. All of the propellant may be charged to the compounding tank at once, or a portion of the propellant may be charged as part of the concentrate with the remainder being charged as a final step, NEAT. The aerosol containers are closed with metering valves, which are designed to deliver a metered amount of the formulation per actuation and include a gasket to prevent leakage of the propellant through the valve. The gasket may be made from any suitable elastomeric material. Gaskets made from white nitrile rubber or ethylene-propylene-diene monomers (EPDM) rubber have been found to be particularly suitable for use with the formulations of the present invention. Depending on the particular application the container may be charged with a predetermined quantity of formulation for single or multiple dosing. Typically, the container is sized for multiple-dosing, and, therefore, it is very important that the formulation delivered is substantially uniform for each dosing. Preferably, the container is charged with a sufficient quantity of the formulation for 100-800 mcg triamcinolone acetonide/actuation for at least 240 actuations. The chemical and physical stability and the pharmaceutical acceptability of the aerosol formulations of the present invention may be determined by conventional analytical techniques well known to those skilled in the art. These include particle size measurement, drug active total assay, degradation assay, drug delivery per actuation, weight delivery per actuation, component/formulation compatibility and extractables, etc. The advantages of the present invention can be further appreciated by reference to the following examples. These examples are intended to illustrate preferred embodiments and are by no means intended to limit the effective scope of the claims. All percentages are by weight unless otherwise specified. |
| PATENT EXAMPLES | available on request |
| PATENT PHOTOCOPY | available on request |
|
Want more information ? Interested in the hidden information ? Click here and do your request. |